You are viewing AANS Neurosurgeon Volume 28, Number 1, 2019. View our current issue, Volume 29, Number 2, 2020

AANS Neurosurgeon | Volume 28, Number 1, 2019


Neoantigen vaccine spurs immune response in glioblastoma

Print Friendly, PDF & Email

Glioblastoma is termed an immunologically ‘cold’ tumor – a disadvantage for treatment with immunotherapy – because the brain tumor contains very few immune cells that are required to generate an immune response against the tumor.

In a report, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells. The neoantigen vaccine approach has been pioneered in the laboratory of Catherine Wu, MD, at Dana-Farber.

“This is the first time it has been shown that a vaccine can generate immune cells against the tumor that can traffic from the bloodstream into a glioblastoma tumor,” said David Reardon, MD, senior author of the study. Reardon is clinical director of the Center for Neuro-Oncology at Dana-Farber.

Click here to read more.


No upcoming events

Comments are closed.

Russell Amundson | January 27, 2019 at 11:35 am

The relative paucity of immune cells within the brain and a BB barrier may preclude antigen activated cells from interacting with the tumor. Would an omental graft to a tumor resection bed create a “mesenchymal capillary interface” that would enhance the “entry” of immune cells from the bloodstream to the GBM’s environment?
(Omental grafts as used for Moya-moya)